Margaret A. Shipp

Margaret A. Shipp, M.D. holds the Douglas S. Miller Chair and serves as Chief of the Division of Hematologic Neoplasia within the Department of Medical Oncology at Dana-Farber Cancer Institute. She is a Professor of Medicine at Harvard Medical School, leading a multi-disciplinary research program focused on aggressive lymphoid malignancies.

Her laboratory specializes in characterizing molecular signatures and genetic alterations in diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin lymphoma (cHL), with emphasis on subtype-specific survival pathways and immune evasion mechanisms. Pioneering work identified chromosome 9p24.1 amplification in cHL as the basis for PD-1 ligand overexpression, directly enabling FDA-approved PD-1 blockade therapies. Current research integrates genomic, transcriptomic, and functional analyses to translate molecular heterogeneity into improved diagnostics and targeted treatments for high-risk patients.

The Shipp Laboratory comprises specialized teams:

• Administrative Team
• Analyses of Immune Evasion Mechanisms and Signaling Pathways in Large B-Cell Lymphomas
• Comprehensive Molecular Signatures of Lymphoid Malignancies
• DNA Damage Repair Pathways in Lymphoid Malignancies
• Genetic Bases of Immune Evasion in Hodgkin Lymphoma
• Multiparametric Analyses of Essential Signaling Pathways
• Physiologic and Oncogenic B-Cell Receptor Signaling

These groups collectively drive the lab's mission to convert molecular discoveries into clinical applications.